Accelerating the translation of therapeutic innovation into clinical impact

Democratizing access to rapid, high-quality biomanufacturing with portable CMC

About Us

A new path for drug developers

Accelerating clinical impact requires innovative outsourcing. Through parallel integration of our development platform with preclinical drug discovery, our comprehensive discovery-to-IND program offers a completely new path for drug developers that is faster, easier, and more predictable.

Built for speed

Our discovery-to-IND program cuts clinical scale-up timelines in half, saving 6-9 months on your way to the clinic. Built for speed, our fixed fees, guaranteed timelines, and minimum yield of GMP drug substance ensure that your critical Phase 1 milestones are predictably achieved.

Win together

Our unique, integrated offering connects discovery with development, our scientists to your development team, and our success to your success, creating a singular focus and lasting collaborative relationship. We share risks and win together.

Our Leadership Team

Jesse McCool PhD


CEO and Co-Founder

Yuk Chun Chiu


Chief Manufacturing Officer

Stephen Hamilton PhD


Chief Technical Officer

Christa Short


VP Process Development

David Schmidt


VP Analytical Development

Mike Brem


Director of Cell Line Development

Dawn Wofford


VP of Quality Assurance and Regulatory Affairs

Our Board

Christian Kanady


Errik Anderson


Jesse McCool PhD


Our Advisory Board

Howard Levine PhD


Roger Lias PhD


Manon Cox PhD


John Mott PhD


Anshul Mangal


Edwin Beale


Mike O’Mara


Peter Rock


Gabriel McCool PhD


Lynne Frick


Marc Helouin


Piotr Bobrowicz PhD


Join our team

Built by scientists for scientists

We are a growing team of drug development professionals who share a passion for speed to clinical impact through collaboration.

Join our community

Connect with our BD team